person

Emanuela M.

Country
Italy
Department
UOC Ematologia Oncologica

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
0
Sites with multiple studies

Has run more than one trial at 0 of 30 partner sites.

Specializations

Hematologic Malignancies

The investigator directs studies on blood‑derived cancers, emphasizing therapeutic strategies for lymphoid and plasma‑cell disorders.

  • Diffuse Large B‑Cell Lymphoma
  • Mantle Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Waldenström’s Macroglobulinemia

Efforts integrate targeted agents and immune‑modulating approaches to improve outcomes in these hematologic diseases.

Genomically Selected Solid Tumors

Research focuses on molecular alterations that drive targeted therapy across a spectrum of solid cancers.

  • KRAS G12C‑mutated non‑small cell lung cancer
  • BRAF V600‑mutant melanoma
  • HER2‑low breast cancer
  • MSI‑High colorectal cancer
  • TMB‑High tumors

The program evaluates precision medicines matched to these genomic signatures.

Immunotherapy and Checkpoint Modulation

Investigator-led trials explore immune‑checkpoint pathways and combination regimens to amplify antitumor immunity.

  • PD‑L1‑positive head and neck squamous cell carcinoma
  • TIGIT inhibition in non‑small cell lung cancer
  • LAG‑3 targeting in melanoma
  • CTLA‑4 blockade in renal cell carcinoma
  • PD‑1 plus anti‑angiogenic therapy

These studies aim to define synergistic immune strategies for durable responses.

Gynecologic and Urologic Oncology

Clinical programs address cancers of the female reproductive tract and the urinary system.

  • Advanced endometrial carcinoma
  • High‑grade serous ovarian cancer
  • Cervical squamous cell carcinoma
  • Metastatic castration‑resistant prostate cancer
  • Urothelial carcinoma of the bladder

Efforts include biomarker‑driven therapies and novel combination regimens.

Rare and Aggressive Tumor Entities

Research targets low‑prevalence malignancies with high unmet medical need.

  • Malignant mesothelioma
  • Neuroendocrine tumors of the lung
  • Anal squamous cell carcinoma
  • Hepatobiliary cancers
  • Soft‑tissue sarcoma

These projects explore innovative therapeutic concepts for historically difficult‑to‑treat cancers.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.